- Home
- URGN vs ASGI Comparison
URGN vs ASGI Comparison
Compare URGN & ASGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- ASGI
- Stock Information
- Founded
- URGN 2004
- ASGI 2019
- Country
- URGN United States
- ASGI United States
- Employees
- URGN N/A
- ASGI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- ASGI Investment Managers
- Sector
- URGN Health Care
- ASGI Finance
- Exchange
- URGN Nasdaq
- ASGI Nasdaq
- Market Cap
- URGN 465.9M
- ASGI 501.0M
- IPO Year
- URGN 2017
- ASGI N/A
- Fundamental
- Price
- URGN $9.67
- ASGI $18.64
- Analyst Decision
- URGN Strong Buy
- ASGI
- Analyst Count
- URGN 7
- ASGI 0
- Target Price
- URGN $37.21
- ASGI N/A
- AVG Volume (30 Days)
- URGN 499.1K
- ASGI 83.3K
- Earning Date
- URGN 05-12-2025
- ASGI 01-01-0001
- Dividend Yield
- URGN N/A
- ASGI 8.76%
- EPS Growth
- URGN N/A
- ASGI N/A
- EPS
- URGN N/A
- ASGI N/A
- Revenue
- URGN $90,398,000.00
- ASGI N/A
- Revenue This Year
- URGN $38.65
- ASGI N/A
- Revenue Next Year
- URGN $118.69
- ASGI N/A
- P/E Ratio
- URGN N/A
- ASGI N/A
- Revenue Growth
- URGN 9.29
- ASGI N/A
- 52 Week Low
- URGN $8.94
- ASGI $14.96
- 52 Week High
- URGN $20.70
- ASGI $18.55
- Technical
- Relative Strength Index (RSI)
- URGN 41.45
- ASGI 61.84
- Support Level
- URGN $8.94
- ASGI $16.70
- Resistance Level
- URGN $10.83
- ASGI $18.55
- Average True Range (ATR)
- URGN 0.79
- ASGI 0.47
- MACD
- URGN -0.07
- ASGI 0.08
- Stochastic Oscillator
- URGN 29.67
- ASGI 98.03
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.